Glenn Heller

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:1775-82. 2007
  2. ncbi A measure of explained risk in the proportional hazards model
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63 Street, New York, NY 10065, USA
    Biostatistics 13:315-25. 2012
  3. ncbi Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 25:2543-53. 2006
  4. ncbi Inference on the limiting false discovery rate and the p-value threshold parameter assuming weak dependence between gene expression levels within subject
    Glenn Heller
    Memorial Sloan Kettering Cancer Center, USA
    Stat Appl Genet Mol Biol 6:Article14. 2007
  5. ncbi Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Med Decis Making 27:380-6. 2007
  6. ncbi Proportional hazards regression with interval censored data using an inverse probability weight
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lifetime Data Anal 17:373-85. 2011
  7. ncbi Organ-derived dendritic cells have differential effects on alloreactive T cells
    Theo D Kim
    Department of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 111:2929-40. 2008
  8. ncbi Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
  9. ncbi Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 64:90-4. 2004
  10. ncbi Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Immunother 30:634-43. 2007

Detail Information

Publications89

  1. ncbi Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:1775-82. 2007
    ..To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules...
  2. ncbi A measure of explained risk in the proportional hazards model
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63 Street, New York, NY 10065, USA
    Biostatistics 13:315-25. 2012
    ..Prostate cancer data are used to demonstrate an analysis incorporating the proposed approach...
  3. ncbi Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 25:2543-53. 2006
    ..The motivating example for this approach is the design of animal studies, where the number of animals per group is typically small...
  4. ncbi Inference on the limiting false discovery rate and the p-value threshold parameter assuming weak dependence between gene expression levels within subject
    Glenn Heller
    Memorial Sloan Kettering Cancer Center, USA
    Stat Appl Genet Mol Biol 6:Article14. 2007
    ..A false discovery rate analysis on a localized prostate cancer data set is used to illustrate the methodology. Simulations are performed to assess the performance of this methodology...
  5. ncbi Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Med Decis Making 27:380-6. 2007
    ..By adjusting for patient risk, this method can provide a more precise assessment of phase 2 treatment efficacy, thereby improving the decision whether to proceed to a phase 3 clinical trial...
  6. ncbi Proportional hazards regression with interval censored data using an inverse probability weight
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lifetime Data Anal 17:373-85. 2011
    ....
  7. ncbi Organ-derived dendritic cells have differential effects on alloreactive T cells
    Theo D Kim
    Department of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 111:2929-40. 2008
    ..A gut-homing phenotype correlates with increased GVHD mortality and morbidity after murine BMT, underlining the importance of the gut in the pathophysiology of GVHD...
  8. ncbi Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
    ....
  9. ncbi Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 64:90-4. 2004
    ..These long-term findings support the continued study of chemotherapy combined with RT as a potential alternative to prolonged androgen deprivation...
  10. ncbi Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Immunother 30:634-43. 2007
    ..We have thus developed a scalable closed process to expand genetically modified, biologically functional CD34+ hematopoietic progenitor cell-derived LCs for phase I clinical trials...
  11. ncbi A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Michael J Morris
    Department of Medicine Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:2378-83; discussion 2383-4. 2007
    ..We defined the antitumor effects of bortezomib alone and in combination with prednisone in patients with progressive, castration resistant metastatic prostate cancer...
  12. ncbi Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 174:758-66. 2005
    ..LCs genetically modified to express fluMP are also more potent stimulators of Ag-specific CD8(+) T cell responses than are peptide-pulsed LCs...
  13. ncbi Rapid androgen cycling as treatment for patients with prostate cancer
    David Feltquate
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:7414-21. 2006
    ..Although the sample size was small, the proportion of patients achieving declining PSA at the end of six cycles was comparable with that reached with continuous androgen depletion therapy...
  14. ncbi Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia
    Sonali Chaudhury
    Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Br J Haematol 140:644-55. 2008
    ..These are encouraging results of T-cell-depleted transplants from alternative donors using fludarabine-based cytoreduction in 18 high-risk patients with Fanconi anaemia, with no evidence of rejection and minimal GVHD...
  15. ncbi Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  16. ncbi A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
    Gopa Iyer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 69:1089-97. 2012
    ....
  17. ncbi Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Elizabeth R Dennis
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:519-24. 2012
    ..Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure...
  18. ncbi Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin
    Craig Sauter
    Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 17:1460-71. 2011
    ....
  19. ncbi Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 176:2357-65. 2006
    ..LCs, transduced with a retroviral vector encoding full-length Ag, stimulate potent CTLs directed against multiple epitopes in a CD4(+) Th cell-dependent manner...
  20. ncbi Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts
    Sharon Avery
    Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 117:3277-85; quiz 3478. 2011
    ..0001). Our findings have important implications for unit selection and provide further insight into double-unit biology...
  21. ncbi Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  22. ncbi Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine
    Elisha Waldman
    Memorial Sloan Kettering Cancer Center, Kettering 406D, Mailbox 111, 1275 York Ave, New York, NY 10021, USA
    Blood 107:1703-11. 2006
    ..Our data suggest that strategies to target the beta7 integrin have the clinical potential to alleviate or prevent GVHD while sparing or potentiating GVT activity...
  23. ncbi IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease
    Teresa Ramirez-Montagut
    Department of Immunology, Laboratory of the Immunology of Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 179:1669-80. 2007
    ....
  24. ncbi Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma
    Sonal Bhandari
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
    Pediatr Blood Cancer 55:76-80. 2010
    ..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
  25. ncbi The association between measures of progression and survival in castrate-metastatic prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:1488-92. 2007
    ..To explore the association between progression-free survival and overall survival time in patients with castration-resistant prostate cancer treated with microtubule-targeted therapies...
  26. ncbi Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities
    Juliet N Barker
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 16:1541-8. 2010
    ..Minority patients in need of allografts, but without suitable matched sibling donors, should be referred for combined URD and CB searches to optimize transplant access...
  27. ncbi Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1
    Emanuela Romano
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA
    Blood 119:5182-90. 2012
    ..These data support the use of mRNA-electroporated LCs, or moDCs supplemented with exogenous rhuIL-15, as vaccines for cancer immunotherapy to break tolerance against self-differentiation antigens shared by tumors...
  28. ncbi TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
    Daniel C Danila
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 60:897-904. 2011
    ..AA treatment results in dramatic declines in prostate-specific antigen (PSA) in some patients and no declines in others, suggesting the presence of molecular determinants of sensitivity in tumors...
  29. ncbi Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
    Adam M Boruchov
    Laboratory of Cellular Immunobiology, Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 115:2914-23. 2005
    ..The data also suggest novel strategies for targeting antigens to the activating or inhibitory FcgammaRs on human DCs to generate either antigen-specific immunity or tolerance...
  30. ncbi IL-17 contributes to CD4-mediated graft-versus-host disease
    Lucy W Kappel
    Department of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 113:945-52. 2009
    ..We conclude that IL-17 is dispensable for GVHD and GVT activity by whole T cells, but contributes to the early development of CD4-mediated GVHD by promoting production of proinflammatory cytokines...
  31. ncbi Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease
    Kevin J Patel
    Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Biol Blood Marrow Transplant 16:435-40. 2010
    ..PES is common after CBT, precedes neutrophil recovery, is distinct from and does not predict for aGVHD, and responds promptly to short-course corticosteroid therapy...
  32. ncbi Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor
    Berrin Ergun-Longmire
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021, USA
    J Clin Endocrinol Metab 91:3494-8. 2006
    ..Continued surveillance is essential...
  33. ncbi Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
    Nidale Tarek
    Department of Pediatrics, Sloan Kettering Institute, New York, NY 10065, USA
    J Clin Invest 122:3260-70. 2012
    ..These results indicate that unlicensed NK cells play a key antitumor role in patients undergoing mAb therapy via antibody-dependent cell-mediated cytotoxicity, thus explaining the potent "missing KIR ligand" benefit in patients with NB...
  34. ncbi Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
    Ekaterina Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:2644-56. 2012
    ....
  35. ncbi Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel
    Gretchen A Gignac
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:966-74. 2008
    ..PFS, however, is vulnerable to inter-study design variability. The authors sought to identify and quantify this variability and the resultant error in PFS across prostate cancer clinical trials...
  36. ncbi DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
    ..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
  37. ncbi Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
    Daniel C Danila
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:7053-8. 2007
    ..We evaluated the association of baseline circulating tumor cell (CTC) number with clinical characteristics and survival in patients with castrate metastatic disease considered for different hormonal and cytotoxic therapies...
  38. ncbi Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen
    Kathleen Beekman
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Urology 65:947-52. 2005
    ..Although achieving an undetectable PSA level does not mean that a patient has been cured, it does establish an endpoint that can be used to identify approaches worthy of study in the Phase III setting...
  39. ncbi Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids
    Richard Enmon
    Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Cancer Res 63:8393-9. 2003
    ..These results suggest that significant gains in treatment effectiveness may be obtained by combining these treatment modalities, warranting additional preclinical investigation...
  40. ncbi T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
    Matthias T Stephan
    Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York 10021, USA
    Nat Med 13:1440-9. 2007
    ..This new strategy of endowing T cells with constitutively expressed costimulatory ligands could be extended to other ligand-receptor pairs and used to enhance any targeted adoptive transfer therapy...
  41. ncbi Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study
    Carrie M Brownstein
    Memorial Sloan-Kettering Cancer Center, Department of Pediatrics, 1275 York Avenue, New York, New York 10021, USA
    J Clin Endocrinol Metab 89:4422-7. 2004
    ....
  42. ncbi Prostate cancer clinical trial end points: "RECIST"ing a step backwards
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:5223-32. 2005
    ..To relate clinical issues to the clinical manifestations of prostate cancers across disease states using the eligibility and outcome criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST)...
  43. ncbi Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Clin Cancer Res 11:3210-6. 2005
    ..We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve as an outcome measure for patients with castrate metastatic prostate cancer treated with antimicrotubule chemotherapy...
  44. ncbi Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
    Mark T Fleming
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:658-67. 2006
    ..It is important to recognize that there are a range of clinical benefits to patients that can improve the quality and possibly the duration of survival, independent of PSA...
  45. ncbi Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL
    Alan M Hanash
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 118:446-55. 2011
    ..IL-21 is thus an exciting target for therapeutic intervention and improvement of clinical transplantation outcomes...
  46. ncbi Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  47. ncbi Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer
    Margaret A Leversha
    Molecular Cytogenetics Core Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 15:2091-7. 2009
    ....
  48. ncbi Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
    Howard I Scher
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 29:2191-8. 2011
    ..To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial...
  49. ncbi Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007
    ..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies...
  50. ncbi Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monoc
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 173:2780-91. 2004
    ..These findings merit further comparisons in clinical trials designed to determine the physiologic relevance of these distinctions in activity between LCs and other DCs...
  51. ncbi End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:3695-704. 2011
    ..We also discuss circulating tumor cells measured with the CellSearch assay, recently cleared by the FDA for monitoring CRPC...
  52. ncbi Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
    Joseph H Chewning
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:1313-23. 2007
    ....
  53. ncbi Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen
    Brian C Betts
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA
    Blood 118:5330-9. 2011
    ....
  54. ncbi The use of back-up units to enhance the safety of unrelated donor cord blood transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 18:648-51. 2012
    ..We demonstrate that back-up units are emergently required in a significant minority of patients, supporting the incorporation of at least 1 back-up unit in cord blood (CB) selection algorithms to enhance CBT safety...
  55. ncbi Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo
    Emanuela Romano
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, USA
    Clin Cancer Res 17:1984-97. 2011
    ..We compared the efficacy of human Langerhans cells (LC) as tumor immunogens in vivo with monocyte-derived dendritic cells (moDC) and investigated how interleukin 15 (IL15) supports optimal DC-stimulated antitumor immunity...
  56. ncbi Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
    ..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
  57. ncbi An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment
    Lamis K Eldjerou
    Allogeneic Bone Marrow Transplantation, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:3999-4006. 2010
    ..Thus, unit dominance is an in vivo phenomenon probably associated with a graft-versus-graft immune interaction mediated by CD34(-) cells...
  58. ncbi Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial
    David Andrew Verbel
    Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Urology 61:142-4. 2003
    ..The design provides investigators increased confidence in making this decision...
  59. ncbi Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 10:233-9. 2009
    ..We aimed to assess circulating tumour cell (CTC) count as a prognostic factor for survival in patients with progressive, metastatic, castration-resistant prostate cancer receiving first-line chemotherapy...
  60. ncbi Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8669-73. 2005
    ....
  61. ncbi Second-line chemotherapy for prostate cancer: patient characteristics and survival
    Kathleen W Beekman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Clin Prostate Cancer 4:86-90. 2005
    ..A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients...
  62. ncbi Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
    Johannes L Zakrzewski
    Department Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Biotechnol 26:453-61. 2008
    ..We conclude that ex vivo generated MHC-disparate T-cell precursors from any donor can be used universally for 'off-the-shelf' immunotherapy, and can be further enhanced by genetic engineering for targeted immunotherapy...
  63. ncbi Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands
    Junli Yu
    Immunology Program, Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 179:5977-89. 2007
    ..These findings have important implications for the resting NK response to viral pathogens and malignancy, for donor selection in allogeneic hemopoietic cell transplantation, and for models of NK tolerance...
  64. ncbi Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
    Katharine C Hsu
    Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Blood 105:4878-84. 2005
    ....
  65. ncbi In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy
    James C Lee
    Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 71:2871-81. 2011
    ..These findings have significant implications for the design of future clinical trials utilizing CAR-based adoptive T-cell therapies of cancer...
  66. ncbi A competing-risks nomogram for sarcoma-specific death following local recurrence
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 22:3515-25. 2003
    ..A competing risks nomogram is produced to estimate the probability of death due to sarcoma for patients who have already developed a local recurrence of their initially treated soft-tissue sarcoma...
  67. ncbi Quantifying the amount of variation in survival explained by prostate-specific antigen
    David A Verbel
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2576-9. 2002
    ..Using a population-based approach, we explore the relationship between PSA and survival and generate a measure to demonstrate the amount of the variation in survival explained by PSA...
  68. ncbi CCR2 is required for CD8-induced graft-versus-host disease
    Theis H Terwey
    Department of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, Kettering 406D, Mailbox 111, 1275 York Ave, New York, NY 10021, USA
    Blood 106:3322-30. 2005
    ..Interestingly, the graft-versus-tumor effect mediated by CCR2-/- CD8+ T cells was preserved, which suggests that interference with T-cell migration by blockade of CCR2 signaling can separate GVHD from GVT activity...
  69. ncbi Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations
    Sharon R Lewin
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY
    Blood 100:2235-42. 2002
    ..T-cell neogenesis, appropriate to age but delayed in adult recipients of T-cell-depleted allografts, justifies interventions to hasten this process and to stimulate desirable cellular immune responses...
  70. ncbi Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Blood 101:1422-9. 2003
    ..Whether these results support a separation of deleterious from beneficial graft-host interactions at the level of antigen presentation, rather than solely at the level of T cells, will require further evaluation...
  71. ncbi Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT)
    Joanne F Chou
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York City, NY 10065, USA
    Biol Blood Marrow Transplant 17:1708-13. 2011
    ....
  72. ncbi The impact of gross total resection on local control and survival in high-risk neuroblastoma
    Michael P La Quaglia
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Surg 39:412-7; discussion 412-7. 2004
    ..Gross total resection should be part of the management of stage 4 neuroblastoma in patients greater than 1 year of age...
  73. ncbi Incorporating follow-up time in M-estimation for survival data
    Glenn Heller
    Department of Epidemiology and Biostatistics, Box 44, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Lifetime Data Anal 10:51-64. 2004
    ..It is easy to implement and the U-statistic framework provides a straightforward development of asymptotic inferential theory for the regression parameters...
  74. ncbi A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions
    Juliet N Barker
    Department of Medicine, Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 15:1596-602. 2009
    ....
  75. ncbi Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy
    Ellin Berman
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cancer 95:1064-70. 2002
    ....
  76. ncbi Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study
    Charles A Sklar
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Endocrinol Metab 87:3136-41. 2002
    ..The increased number of SN, particularly in survivors of acute leukemia, is of concern, but the data need to be interpreted with caution given the small number of events...
  77. ncbi Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
    ..Strikingly, the CD4(+)IFN-gamma(+) cell fractions were not cytotoxic against EBV-transformed or allogeneic targets...
  78. ncbi Altered bone and mineral metabolism in patients receiving imatinib mesylate
    Ellin Berman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 354:2006-13. 2006
    ..We observed that hypophosphatemia developed in some patients with either chronic myelogenous leukemia or gastrointestinal stromal tumors who were receiving imatinib...
  79. ncbi Lehmann family of ROC curves
    Mithat Gonen
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63 Street, New York, NY 10021, USA
    Med Decis Making 30:509-17. 2010
    ..Evaluation of the underlying assumptions, model fitting, and model selection can be performed using any off-the-shelf proportional hazards statistical software package...
  80. ncbi Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data
    Cami S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Health Econ Health Policy 8:37-51. 2010
    ....
  81. ncbi Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
    ..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
  82. ncbi Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation
    Nina Cohen
    Department of Medicine, Infectious Disease, New York, New York, USA
    Biol Blood Marrow Transplant 15:1337-41. 2009
    ..Our findings demonstrate no adverse effect on the times to neutrophil or platelet engraftment with linezolid use. Larger prospective studies are needed to fully determine the hematologic safety of linezolid in patients undergoing HSCT...
  83. ncbi Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  84. ncbi LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease
    Aleksandra Petrovic
    Departmentof Pedicatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 103:1542-7. 2004
    ..We conclude that the alpha(4)beta(7) integrin is important for the invasion of alloreactive donor T cells into the gut and the subsequent development of intestinal GVHD and overall GVHD morbidity and mortality...
  85. ncbi Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes
    Guenther Koehne
    Allogeneic Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Biotechnol 21:405-13. 2003
    ..This technique for imaging the migration of ex vivo-transduced antigen-specific T cells in vivo is informative, nontoxic, and potentially applicable to humans...
  86. ncbi Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
    David R Shaffer
    Genitourinary Oncology Service, Immunicon Corporation, Huntingdon Valley, Pennsylvania, USA
    Clin Cancer Res 13:2023-9. 2007
    ..We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer...
  87. ncbi Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study
    Rochelle Bagatell
    Department of Pediatrics and Steele Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    Clin Cancer Res 13:1783-8. 2007
    ....
  88. ncbi Picking the winners in a sea of plenty
    Howard I Scher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 8:400-4. 2002
    ....
  89. ncbi 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts
    David B Solit
    Program in Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:986-93. 2002
    ..These results suggest that this drug may represent a new strategy for the treatment of prostate cancer...